Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28599
Title: Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection.
Austin Authors: Phetsouphanh, Chansavath;Darley, David R;Wilson, Daniel B;Howe, Annett;Munier, C Mee Ling;Patel, Sheila K ;Juno, Jennifer A;Burrell, Louise M ;Kent, Stephen J;Dore, Gregory J;Kelleher, Anthony D;Matthews, Gail V
Affiliation: Medicine (University of Melbourne)
Melbourne Sexual Health Centre, Infectious Diseases Department, Alfred Health, Central Clinical School, Monash University, Melbourne, Victoria, Australia
The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
St Vincent's Hospital, Darlinghurst, New South Wales, Australia
Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia
Department of Mathematics and Statistics, Boston University, Boston, MA, USA
Issue Date: Feb-2022
Date: 2022-01-13
Publication information: Nature Immunology 2022; 23(2): 210-216
Abstract: A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we studied individuals with LC compared to age- and gender-matched recovered individuals without LC, unexposed donors and individuals infected with other coronaviruses. Patients with LC had highly activated innate immune cells, lacked naive T and B cells and showed elevated expression of type I IFN (IFN-β) and type III IFN (IFN-λ1) that remained persistently high at 8 months after infection. Using a log-linear classification model, we defined an optimal set of analytes that had the strongest association with LC among the 28 analytes measured. Combinations of the inflammatory mediators IFN-β, PTX3, IFN-γ, IFN-λ2/3 and IL-6 associated with LC with 78.5-81.6% accuracy. This work defines immunological parameters associated with LC and suggests future opportunities for prevention and treatment.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28599
DOI: 10.1038/s41590-021-01113-x
ORCID: http://orcid.org/0000-0001-6617-5995
http://orcid.org/0000-0002-9721-101X
http://orcid.org/0000-0002-6419-142X
http://orcid.org/0000-0002-9072-1017
http://orcid.org/0000-0003-1863-7539
http://orcid.org/0000-0002-8539-4891
http://orcid.org/0000-0002-0009-3337
http://orcid.org/0000-0002-0626-1899
Journal: Nature Immunology
PubMed URL: 35027728
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35027728/
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

34
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.